Management of Hepatitis C Infection
Summary
- AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] guidelines recommend glecaprevir/pibrentasvir and sofosbuvir/velpatasvir as preferred options for genotype 3 HCV–infected treatment-naive patients
- EASL guidelines recommend DAA-based regimens for patients with genotype 3 HCV infection (Management Guidelines)[EASL HCV]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment